Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma
1 other identifier
interventional
50
0 countries
N/A
Brief Summary
The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with ovarian carcinoma.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_2
Started Jul 2015
Longer than P75 for phase_2
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 29, 2015
CompletedFirst Posted
Study publicly available on registry
July 1, 2015
CompletedStudy Start
First participant enrolled
July 1, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2038
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 1, 2040
February 23, 2016
February 1, 2016
22.9 years
June 29, 2015
February 21, 2016
Conditions
Outcome Measures
Primary Outcomes (1)
Recurrence-free survival
Recurrence-free survival (RFS) was defined as the time from the date of RFA to the date of recurrence or the date of the last follow-up.
1 year
Secondary Outcomes (1)
Adverse events
4 weeks
Study Arms (2)
RFA alone
NO INTERVENTIONPatients undergo radiofrequency ablation alone.
RFA+CIK
EXPERIMENTALAutologous cytokine-induced killer cells were transfer via venous one week after RFA Interventions
Interventions
Radiofrequency ablation is performed percutaneously under CT/US guidance
The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
Eligibility Criteria
You may qualify if:
- patients diagnosed with FIGO stage II ovarian carcinoma;
- cytoreductive surgery performed and 6 courses of platinum-based chemotherapy completed;
- medical records maintain comprehensive data on treatment and follow-up;
- no history of previous malignancies.
You may not qualify if:
- neoadjuvant chemotherapy applied;
- less than 6 courses of chemotherapy or more than 6 courses of chemotherapy completed;
- medical records maintain incomplete data on treatment or follow-up;
- history of previous malignancy.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 29, 2015
First Posted
July 1, 2015
Study Start
July 1, 2015
Primary Completion (Estimated)
June 1, 2038
Study Completion (Estimated)
June 1, 2040
Last Updated
February 23, 2016
Record last verified: 2016-02